Relay Therapeutics, Inc.
RLAY · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1 | $1 | $2 | $3 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $1 | $2 | $3 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -60.8% | 1,749.8% | -54.4% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -3,799.4% | -1,464.6% | -22,217.4% | -7,364.9% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -3,374.7% | -1,338.7% | -21,036.1% | -12,012.9% |
| EPS Diluted | -2.36 | -2.79 | -2.59 | -3.82 |
| % Growth | 15.4% | -7.7% | 32.2% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |